For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Admission of cancer funding fumble no surprise to oncologist
Wednesday 31 July 2024, 03:30 AM

Cancer specialist George Laking welcomes the newly funded cancer drugs but says population growth means more is needed [Image: Supplied]
Did public backlash or campaign promises drive the Government to provide a $604 million funding boost for cancer drugs? Stephen Forbes reports
In a nutshell
The National Party’s campaign commitment to fund a specific list of drugs was problematic, as it undermined Pharmac’s ability to n, News Red w/ Pale
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.